Vectorbuilder Inc.

Vectorbuilder Inc., a Chicago-based biotechnology firm, provides custom molecular biology and gene delivery services to federal research agencies as a prime contractor across small business set-aside and full-and-open competitive procurements. The company specializes in adeno-associated virus packaging, plasmid and DNA synthesis, molecular cloning, stable cell line generation, and lipid nanoparticle encapsulation — capabilities anchored in thirteen purchase orders totaling $361 thousand in combined potential value since 2022. Vectorbuilder competes across both Total Small Business set-asides and unrestricted full-and-open tenders; roughly 31% of recent awards (two of thirteen) carry small business set-aside designations, while the remainder compete without set-aside restrictions.

Vectorbuilder's customer base centers on National Institutes of Health institutes and the Department of Veterans Affairs. The top five customer agencies by award count account for 62% of awards, led by the National Institutes of Health National Cancer Institute (two awards, $30 thousand combined potential value), the National Human Genome Research Institute (two awards, $12 thousand), and the National Institute of Neurological Disorders and Stroke (two awards, $32 thousand combined potential value), with single awards distributed across the USDA Agricultural Research Service, the VA Veterans Health Administration VISN 1, and others. Dollar concentration diverges sharply from award volume: the VA Veterans Health Administration Veterans Integrated Service Network 22 anchors 76% of the top customers' combined potential value with a single $160 thousand two-year molecular cloning contract awarded in September 2023, while NIH institutes collectively drive the award count but carry smaller per-engagement values ranging from $11.4 thousand to $32 thousand. Recent representative work includes a $20.3 thousand Total Small Business set-aside purchase order with the USDA Agricultural Research Service (awarded March 3, 2026) for synthesis of self-amplifying RNA constructs and lipid nanoparticle encapsulation to develop a poultry vaccine, a $28.8 thousand sole-source purchase order with the VA Providence Medical Center for AAV9 vector cloning and ultra-purification supporting pulmonary hypertension research, and a $23.4 thousand Total Small Business set-aside with the Shared Services Center for stable cell line generation. Award activity has grown modestly — five awards in 2024 compared to two in 2023 — though the source captures only one award in 2025 and one in 2026 to date. One award ($20.3 thousand) reaches ultimate completion inside the next twenty-four months and faces recompete exposure. Vectorbuilder operates exclusively as a prime contractor with no subcontract footprint in the source data, and does not sit on government-wide vehicles or BPAs.

VectorBuilder is a rapidly growing biotechnology company that has established itself as a global leader in a range of life sciences products and services, including vector cloning, virus packaging, library construction, stable cell line generation, Covid-19 research reagents, and GMP manufacturing of clinical-grade plasmid DNA and viruses. VectorBuilder's revolutionary online vector design platform has become highly popular with researchers and Biotech companies around the world for its rich functionalities and highly intuitive user interface.